Roche has secured two separate discovery partnerships with Atavistik Bio and Earendil Labs, expanding its pipeline of new candidates through continued dealmaking in discovery-stage development. The agreements add external programs in the drug-discovery stage and keep Roche’s option set active as it targets new modalities and differentiated biology. Separately, Roche also signed a backloaded $2 billion deal with Atavistik to develop allosteric cardiometabolic drugs, indicating the company is placing repeated strategic bets on the same biotech’s chemistry and platform capabilities. For the industry, the combined Roche activity reinforces that discovery partnerships remain a key lever for Big Pharma to diversify modality and risk while feeding downstream development options.